COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that results from its Phase 2 trial of ZS-9, a novel investigational treatment for hyperkalemia, will be presented in a poster session at the American College of Cardiology (ACC) 63rd Annual Scientific Session & Expo in Washington, D.C. The Phase 2 proof-of-concept study assessed the safety and efficacy of ZS-9 in treating chronic kidney disease (CKD) patients with hyperkalemia, a life-threatening condition that is characterized by higher than normal levels of potassium (K+) in the blood serum.
Help employers find you! Check out all the jobs and post your resume.
